Cover Image
市場調查報告書

Mabion SA:產品平台分析

Mabion SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 311915
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Mabion SA:產品平台分析 Mabion SA - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 27 Pages
簡介

本報告提供Mabion SA的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台的分析與最新趨勢等資訊。

Mabion SA的基本資料

Mabion SA概要

  • 主要資訊
  • 企業資料

Mabion SA:R&D概要

  • 主要的治療範圍

Mabion SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Mabion SA:開發中產品概況

  • 後期開發中產品
    • 第三階段有的產品/聯合治療模式
  • 初期階段有的開發中產品
    • 前臨床階段的產品/聯合治療模式

Mabion SA:藥物簡介

  • rituximab生技仿製藥
  • adalimumab生技仿製藥
  • bevacizumab生技仿製藥
  • cetuximab生技仿製藥
  • ranibizumab生技仿製藥
  • trastuzumab生技仿製藥

Mabion SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Mabion SA:最近的開發平台趨勢

Mabion SA:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07299CDB

Summary

Global Markets Direct's, 'Mabion SA - Product Pipeline Review - 2015', provides an overview of the Mabion SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mabion SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mabion SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mabion SA's pipeline products

Reasons to buy

  • Evaluate Mabion SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mabion SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mabion SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mabion SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mabion SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mabion SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mabion SA Snapshot
    • Mabion SA Overview
    • Key Information
    • Key Facts
  • Mabion SA - Research and Development Overview
    • Key Therapeutic Areas
  • Mabion SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Mabion SA - Pipeline Products Glance
    • Mabion SA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Mabion SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Mabion SA - Drug Profiles
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mabion SA - Pipeline Analysis
    • Mabion SA - Pipeline Products by Target
    • Mabion SA - Pipeline Products by Route of Administration
    • Mabion SA - Pipeline Products by Molecule Type
    • Mabion SA - Pipeline Products by Mechanism of Action
  • Mabion SA - Recent Pipeline Updates
  • Mabion SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mabion SA, Key Information
  • Mabion SA, Key Facts
  • Mabion SA - Pipeline by Indication, 2015
  • Mabion SA - Pipeline by Stage of Development, 2015
  • Mabion SA - Monotherapy Products in Pipeline, 2015
  • Mabion SA - Phase III, 2015
  • Mabion SA - Preclinical, 2015
  • Mabion SA - Pipeline by Target, 2015
  • Mabion SA - Pipeline by Route of Administration, 2015
  • Mabion SA - Pipeline by Molecule Type, 2015
  • Mabion SA - Pipeline Products by Mechanism of Action, 2015
  • Mabion SA - Recent Pipeline Updates, 2015
  • Mabion SA, Other Locations

List of Figures

  • Mabion SA - Pipeline by Top 10 Indication, 2015
  • Mabion SA - Pipeline by Stage of Development, 2015
  • Mabion SA - Monotherapy Products in Pipeline, 2015
  • Mabion SA - Pipeline by Top 10 Target, 2015
  • Mabion SA - Pipeline by Top 10 Route of Administration, 2015
  • Mabion SA - Pipeline by Top 10 Molecule Type, 2015
  • Mabion SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top